Global approaches to post-approval safety are changing rapidly around the world. With a much greater interest in watching the performance of new drugs and devices once they come to market. If you are thinking about bringing a new drug or medical device to the market in Europe, you need to know what regulators are expecting, in particular since the new pharmacovigilance legislation was implemented in 2012.

See how QuintilesIMS can help you navigate the challenges and the opportunities of this new era in Post-Authorization Safety Studies. For further information